# Research progress on the effects of M1/M2 macrophages on the differentiation and maturation of stem cell-derived cardiomyocytes: a review

**Authors:** Xi Wu, Fan Zhou, Junsheng Mu

PMC · DOI: 10.1186/s13287-026-04938-1 · 2026-02-15

## TL;DR

This review explores how M1 and M2 macrophages influence the development and function of stem cell-derived heart cells, offering insights into improving their use in cardiac regeneration.

## Contribution

The review provides an integrated perspective on how macrophage polarization affects stem cell-derived cardiomyocyte maturation and proposes new therapeutic strategies.

## Key findings

- M1 macrophages hinder SC-CM maturation by inhibiting the Wnt/β-catenin pathway and promoting an immature glycolytic state.
- M2 macrophages support SC-CM maturation through trophic factors and metabolic reprogramming toward oxidative phosphorylation.
- Strategies like co-transplantation and engineered exosomes are suggested to leverage macrophage polarization for better cardiac regeneration.

## Abstract

Stem cell-derived cardiomyocytes (SC-CMs) represent a promising cell source for cardiac regenerative medicine, disease modeling, and drug screening. However, their clinical translation faces significant challenges, including functional immaturity, poor long-term survival, and inadequate integration with host tissue following transplantation. The immune microenvironment, particularly the dynamic polarization of macrophages into pro-inflammatory (M1) or reparative (M2) phenotypes, is increasingly recognized as a critical regulator of cardiac repair, yet a systematic understanding of its specific effects on SC-CM fate remains incomplete. This review aims to comprehensively evaluate the dual regulatory roles of M1 and M2 macrophages on the differentiation efficiency, structural and functional maturation, and in vivo transplantation efficacy of SC-CMs. A systematic literature search was conducted in PubMed, Web of Science, Nature, and CNKI for relevant studies published from database inception to July 2025. After screening, 92 articles were included for analysis. The synthesized evidence demonstrates that M1 macrophages and their secreted factors (e.g., TNF-α, IL-1β) impede cardiac differentiation by inhibiting the Wnt/β-catenin pathway, disrupt sarcomeric organization and calcium handling, and maintain SC-CMs in a glycolytic, immature state. In contrast, M2 macrophages enhance SC-CM maturation by providing trophic support (e.g., IGF-1, HGF), promoting electrophysiological maturation and metabolic reprogramming towards oxidative phosphorylation, and facilitating angiogenesis via VEGF. The novelty of this review lies in its integrated perspective on macrophage-driven immunomodulation as a central axis for SC-CM maturation. Furthermore, it discusses emerging therapeutic strategies—such as optimized transplantation timing, co-transplantation with immunomodulatory cells, engineered exosomes, and smart biomaterials—that leverage macrophage polarization to create a favorable microenvironment for SC-CMs. Ultimately, harnessing macrophage-SC-CM crosstalk is a crucial step toward advancing clinically effective and immunologically informed cardiac regeneration therapies.

## Linked entities

- **Proteins:** TNF (tumor necrosis factor), IL1B (interleukin 1 beta), IGF1 (insulin like growth factor 1), HGF (hepatocyte growth factor), VEGFA (vascular endothelial growth factor A)

## Full-text entities

- **Genes:** Il10 (interleukin 10) [NCBI Gene 16153] {aka CSIF, If2a, Il-10}, SIRT3 (sirtuin 3) [NCBI Gene 23410] {aka SIR2L3}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, KCNJ2 (potassium inwardly rectifying channel subfamily J member 2) [NCBI Gene 3759] {aka ATFB9, HHBIRK1, HHIRK1, IRK1, KIR2.1, LQT7}, JAK2 (Janus kinase 2) [NCBI Gene 3717] {aka JTK10}, PRKAB1 (protein kinase AMP-activated non-catalytic subunit beta 1) [NCBI Gene 5564] {aka AMPK, HAMPKb}, LYVE1 (lymphatic vessel endothelial hyaluronan receptor 1) [NCBI Gene 10894] {aka CRSBP-1, HAR, LYVE-1, XLKD1}, RYR2 (ryanodine receptor 2) [NCBI Gene 6262] {aka ARVC2, ARVD2, RYR-2, RyR, VACRDS, VTSIP}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, PEBP1 (phosphatidylethanolamine binding protein 1) [NCBI Gene 5037] {aka HCNP, HCNPpp, HEL-210, HEL-S-34, HEL-S-96, PBP}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, PPARGC1A (PPARG coactivator 1 alpha) [NCBI Gene 10891] {aka LEM6, PGC-1(alpha), PGC-1alpha, PGC-1v, PGC1, PGC1A}, NKX2-5 (NK2 homeobox 5) [NCBI Gene 1482] {aka CHNG5, CSX, CSX1, HLHS2, NKX2.5, NKX2E}, CD80 (CD80 molecule) [NCBI Gene 941] {aka B7, B7-1, B7.1, BB1, CD28LG, CD28LG1}, Stat6 (signal transducer and activator of transcription 6) [NCBI Gene 20852], TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, Il13 (interleukin 13) [NCBI Gene 16163] {aka Il-13}, HGF (hepatocyte growth factor) [NCBI Gene 3082] {aka DFNB39, F-TCF, HGFB, HPTA, SF}, CD86 (CD86 molecule) [NCBI Gene 942] {aka B7-2, B7.2, B70, BU63, CD28LG2, CD86 v6}, ACTN1 (actinin alpha 1) [NCBI Gene 87] {aka BDPLT15}, VEGFB (vascular endothelial growth factor B) [NCBI Gene 7423] {aka VEGFL, VRF}, GJA1 (gap junction protein alpha 1) [NCBI Gene 2697] {aka AVSD3, CMDR, CX43, EKVP, EKVP3, GJAL}, FASLG (Fas ligand) [NCBI Gene 356] {aka ALPS1B, APT1LG1, APTL, CD178, CD95-L, CD95L}, Il4 (interleukin 4) [NCBI Gene 16189] {aka BSF-1, Il-4}, CCR2 (C-C motif chemokine receptor 2) [NCBI Gene 729230] {aka CC-CKR-2, CCR-2, CCR2A, CCR2B, CD192, CKR2}, SIRT1 (sirtuin 1) [NCBI Gene 23411] {aka SIR2, SIR2L1, SIR2alpha}, CACNA1C (calcium voltage-gated channel subunit alpha1 C) [NCBI Gene 775] {aka CACH2, CACN2, CACNA1C-IT2, CACNL1A1, CCHL1A1, CaV1.2}, MIR21 (microRNA 21) [NCBI Gene 406991] {aka MIRN21, hsa-mir-21, miR-21, miRNA21}, Arg1 (arginase, liver) [NCBI Gene 11846] {aka AI, Arg-1, PGIF}, CDH2 (cadherin 2) [NCBI Gene 1000] {aka ACOGS, ADHD8, ARVD14, CD325, CDHN, CDw325}, HMGB1 (high mobility group box 1) [NCBI Gene 3146] {aka HMG-1, HMG1, HMG3, SBP-1}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, TNNT2 (troponin T2, cardiac type) [NCBI Gene 7139] {aka CMD1D, CMH2, CMPD2, LVNC6, RCM3, TnTC}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, IL23A (interleukin 23 subunit alpha) [NCBI Gene 51561] {aka IL-23, IL-23A, IL23P19, P19, SGRF}, MIR146A (microRNA 146a) [NCBI Gene 406938] {aka MIRN146, MIRN146A, miR-146a, miRNA146A}, GATA4 (GATA binding protein 4) [NCBI Gene 2626] {aka ASD2, TACHD, TOF, VSD1}, Mrc1 (mannose receptor, C type 1) [NCBI Gene 17533] {aka CD206, MR}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, TREM2 (triggering receptor expressed on myeloid cells 2) [NCBI Gene 54209] {aka AD17, PLOSL2, TREM-2, Trem2a, Trem2b, Trem2c}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, CSF1R (colony stimulating factor 1 receptor) [NCBI Gene 1436] {aka BANDDOS, C-FMS, CD115, CSF-1R, CSFR, FIM2}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CD163 (CD163 molecule) [NCBI Gene 9332] {aka M130, MM130, SCARI1}, IL12B (interleukin 12B) [NCBI Gene 3593] {aka CLMF, CLMF2, IL-12B, IMD28, IMD29, NKSF}, BMP1 (bone morphogenetic protein 1) [NCBI Gene 649] {aka OI13, PCOLC, PCP, TLD}, FAS (Fas cell surface death receptor) [NCBI Gene 355] {aka ALPS1A, APO-1, APT1, CD95, FAS1, FASTM}, MRC1 (mannose receptor C-type 1) [NCBI Gene 4360] {aka CD206, CLEC13D, CLEC13DL, MMR, MRC1L1, bA541I19.1}, TBK1 (TANK binding kinase 1) [NCBI Gene 29110] {aka AIARV, FTDALS4, IIAE8, NAK, T2K}, MYH14 (myosin heavy chain 14) [NCBI Gene 79784] {aka DFNA4, DFNA4A, FP17425, MHC16, MYH17, NMHC II-C}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}
- **Diseases:** ventricular remodeling (MESH:D020257), Inflammation (MESH:D007249), arrhythmia (MESH:D001145), hypertension (MESH:D006973), hypertrophy (MESH:D006984), heart failure (MESH:D006333), necrotic myocardium (MESH:D017682), necrotic (MESH:D009336), hypoxia (MESH:D000860), cancer (MESH:D009369), Fibrosis (MESH:D005355), MI (MESH:D009203), ischemic (MESH:D002545), arrhythmic (OMIM:212500), PSC (MESH:D015209), ischemia (MESH:D007511), diabetes (MESH:D003920), mitochondrial dysfunction (MESH:D028361), pancreatic cancer (MESH:D010190), Cardiovascular disease (MESH:D002318), tumorigenicity (MESH:D002471), scar (MESH:D002921), cardiac disease (MESH:D006331), infarct (MESH:D007238), death (MESH:D003643), cardiac rupture (MESH:D006341)
- **Chemicals:** ATP (MESH:D000255), lipopolysaccharide (MESH:D008070), acetylcholine (MESH:D000109), sodium (MESH:D012964), ROS (MESH:D017382), Resveratrol (MESH:D000077185), Berberine (MESH:D001599), oxygen (MESH:D010100), Astragaloside IV (MESH:C052064), fatty acid (MESH:D005227), M1 (MESH:C400939), calcium (MESH:D002118), NO (MESH:D009569)
- **Species:** Sus scrofa (pig, species) [taxon 9823], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC13011457/full.md

---
Source: https://tomesphere.com/paper/PMC13011457